MedTrace Logo

Efficacy and Safety of IQP-VV-102 in Weight Management

NCT01681069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-11-06

Study results available
· View outcomes & findings →

Summary

Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Conditions

Interventions

DIETARY_SUPPLEMENT

IQP-VV-102

OTHER

Placebo

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Barbara Grube, MD · Practice for General Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681069 on ClinicalTrials.gov